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DOI 10.1016/j.ccr.2011.10.012SUMMARYUsing a mouse model recapitulating the main features of human chronic myelogenous leukemia (CML), we
uncover the hierarchy of leukemic stem and progenitor cells contributing to disease pathogenesis. We refine
the characterization of CML leukemic stem cells (LSCs) to the most immature long-term hematopoietic stem
cells (LT-HSCs) and identify some important molecular deregulations underlying their aberrant behavior. We
find that CML multipotent progenitors (MPPs) exhibit an aberrant B-lymphoid potential but are redirected
toward the myeloid lineage by the action of the proinflammatory cytokine IL-6. We show that BCR/ABL
activity controls Il-6 expression thereby establishing a paracrine feedback loop that sustains CML develop-
ment. These results describe how proinflammatory tumor environment affects leukemic progenitor cell fate
and contributes to CML pathogenesis.INTRODUCTION
Chronic myelogenous leukemia (CML) is a clonal myeloprolifera-
tive neoplasm (MPN) characterized by the t(9;22)(q34;q11) recip-
rocal translocation, which leads to the expression of the
BCR/ABL fusion protein (Savona and Talpaz, 2008). BCR/ABL
is a hyperactive and deregulated tyrosine kinase that promotes
leukemic growth by disrupting a broad range of signaling path-
ways involved in cell survival, proliferation, and differentiation.
Clinically, the natural course of the disease includes three dis-
tinct phases (Perrotti et al., 2010). The initial phase is character-
ized by a progressive myeloid expansion, with accumulation of
myeloid progenitors and mature granulocytes in the bone mar-
row (BM) and peripheral blood (PB). Upon acquisition of sec-
ondary mutations, this chronic phase evolves through an accel-
erated phase into an acute leukemia-like blast crisis involvingSignificance
Here, we show that the clinically relevant CML-LSCs are solely
features of these cells that could be amenable to targeted the
compete normal LT-HSCs due to major alterations in their cell
over, we identify two leukemic progenitors, which are devoid o
We demonstrate that BCR/ABL controls expression of the pro
acting on leukemicMPPs to promotemyeloid development at t
blocking therapy as a potential strategy to control CML develo
Caneither myeloid, B lymphoid or myeloid/lymphoid biphenotypic
cells. During the chronic phase, CML cells have been shown to
be functionally heterogeneous and capable ofmaintaining a hier-
archical organization caricaturing normal hematopoiesis, with
only a fraction of the cells being actually responsible for disease
maintenance and propagation, thus behaving as leukemia-initi-
ating stem cells (LSCs) (Passegue´ and Weisman, 2005).
The existence of a LSC compartment has fundamental conse-
quences for CML therapy (Savona and Talpaz, 2008). Although
BCR/ABL tyrosine kinase inhibitors (TKIs) are remarkably effec-
tive in inducing remission in chronic phase patients, they are not
effective against CML-LSCs, which can persist and regenerate
the disease upon drug discontinuation. Why CML-LSCs are
refractory to TKIs remains a matter of debate. One explanation
could be a failure to achieve an efficient therapeutic concentra-
tion of TKIs in CML-LSCs due to their particular location incontained in the LT-HSC compartment, and identify aberrant
rapy. We find that CML-LSCs are hyperproliferative and out
cycle control and deregulation of the Notch pathway. More-
f self-renewal activity but are critical for CML pathogenesis.
inflammatory cytokine IL-6 and establishes a paracrine loop
he expense of lymphoid differentiation. This finding adds IL-6
pment.
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Figure 1. CML Hematopoiesis in Inducible
BCR/ABL Transgenic Mice
(A) Experimental scheme. Double transgenic mice
(BA) were maintained in presence of doxycycline
(20 mg/l) in drinking water until 5 weeks of age
before inducting BCR/ABL by doxycycline with-
drawal. WT and single transgenic littermates
treated with the same regimen were used as
controls (Cnt) and all the mice were analyzed
6 weeks after doxycycline withdrawal.
(B) Hematopoietic features in CML mice. Graphs
show the percentages of mature cells detected in
PB, BM, and spleen of Cnt and BA mice. Results
are expressed as mean ± SD (n R 8; *p % 102,
**p% 103, ***p% 104).
(C) Weight, morphology and hematoxylin and
eosin (H&E) staining of spleen from Cnt and BA
mice.
(D) Total cellularity and cell number for each
progenitor compartment in BM and spleen of Cnt
andBAmice. Results are expressed asmean ± SD
(nR 6; *p% 102, **p% 103, ***p% 104, ****p%
105).
(E) H&E staining of BM (sternum) section from Cnt
and BA mice. The arrowhead indicates myelofi-
brotic tissue.
(F) Gordon and Sweet’s reticulin staining of BM
(sternum) section from Cnt and BA mice. The
arrowhead indicates myelofibrotic tissue. See also
Figure S1.
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IL-6 in CML Pathogenesisprotective niches, their high content of drug efflux pumps and/or
their enhanced expression of BCR/ABL (Barnes and Melo,
2006). A recent study suggests an alternative scenario wherein
CML-LSCs are not killed by TKIs as other CML cells because
they are actually insensitive to BCR/ABL inhibition (Corbin
et al., 2011). This model predicts that BCR/ABL-based therapies
will not eliminate CML-LSCs and highlights the need for ap-
proaches targeting alternative pathways that are critical for
LSCs maintenance. A refined characterization and better under-
standing of CML-LSC biology is therefore essential for the estab-
lishment of targeted anti-LSC therapies and the development of
curative treatment for CML.
Historically, BCR/ABL retroviral transduction/transplantation
studies in the mouse have been instrumental in showing that
BCR/ABL is the direct cause of CML and in validating this onco-
gene as a drug target. Furthermore, these studies were used to
demonstrate that CML-LSCs are contained in the hematopoietic662 Cancer Cell 20, 661–673, November 15, 2011 ª2011 Elsevier Inc.stem cell (HSC) enriched Lin/Sca-1+/
c-Kit+ (LSK) fraction of the BM (Hu et al.,
2006), and that developmental pathways
controlling HSC function are essential
for CML-LSCs generation and CML de-
velopment (Warr et al., 2011). However,
such experimental approaches have in-
herent limitations due to the constraints
imposed by the retroviral transduction,
and the use of irradiated recipients for
transplantation. In this context, the Scl/
Tal1-tTA x TRE-BCR/ABL double trans-
genic mice, which allow for inducibleBCR/ABL expression in HSCs and CML development in adult
mice (Koschmieder et al., 2005), represent a valuable alternative
to study CML pathogenesis and to test therapies in vivo (Zhang
et al., 2010). Here, we used this inducible BCR/ABL transgenic
mouse model to understand the effect of BCR/ABL activity on
hematopoietic development.
RESULTS
CML Development Is Associated with a Profound
Reorganization of BM Hematopoiesis
Scl/Tal1-tTA and TRE-BCR/ABL transgenic mice were bred in
the presence of doxycycline, and BCR/ABL (BA+) expression
was induced by doxycycline withdrawal 5 weeks after birth (Fig-
ure 1A). All induced double transgenic mice (thereafter called BA
mice) progressively developed a CML-like disease associated
with a severe myeloid cell expansion and reduction in B and
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Figure 2. Refining the Identity of CML Leukemic
Stem Cells
(A) Experimental scheme. Cells were isolated by flow
cytometry from Cnt or BA mice (CD45.2) 5 weeks after
doxycycline withdrawal. Four thousand (LT-HSC, ST-
HSC, CD48+, MPP, and CLP) or 40,000 (CMP and GMP)
cells were transplanted into sublethally irradiated CD45.1
recipients (denoted tCnt and tBA). Transplanted mice
were bled at several time points, and BM analyses were
performed at 35 days posttransplantation.
(B) Kinetics of hematopoietic reconstitution in PB. The
upper graph indicates the overall percentage of CD45.2
chimerism. The lower left and right graphs show the per-
centage of donor-derived myeloid (Mac1+) and lymphoid
(B220+/CD3+) cells, respectively. Results are expressed as
mean ± SEM (n = 2–6). y, Cohorts found moribund at the
time of analysis; (y), Cohort with partial mortality (two out of
seven).
(C) Hematopoietic reconstitution in BM. Histograms show
the average percentage (n = 2–5) of donor-derivedmyeloid
(Mac1+, black) and lymphoid (B220+/CD3+, gray) cells.
(D) Reorganization of the immature BM compartments in
transplanted mice. Representative FACS plots showing
the change in frequency in mice transplanted with 4000
Cnt or BA+ LT-HSCs and ST-HSCs. See also Figure S2.
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IL-6 in CML PathogenesisT cell lineages in the BM, spleen and PB (Figures 1A and 1B; see
Figure S1A available online), and splenomegaly (Figure 1C). BA
mice also became moribund 6 weeks after induction. In con-
trast to other genetic backgrounds (Koschmieder et al., 2005),
no lymphoid disorders were observed in over 100 BA mice on
a pure C57Bl/6 background. CML development in 5–6-weeks-
induced BA mice was associated with a 2-fold reduction in BM
cellularity (Figure 1D) and the development of a profound myelo-
fibrosis (Figures 1E and 1F), as previously described in 30% of
CML patients (Buesche et al., 2007). Analysis of the LSK com-
partment showed a severe reduction in the number of LT-HSCs
(LSK/Flk2/CD48/CD150+) and ST-HSCs (LSK/Flk2/CD48/
CD150), which was accompanied by an expansion of the
nonself-renewing CD48+ cells (LSK/Flk2/CD48+), whereas the
number of MPPs (LSK/Flk2+) remained unchanged (Figure 1D;
Figure S1B). Analysis of the myeloid progenitor compartment
indicated a severe reduction in the number of common mye-
loid progenitors (CMP: LK/CD34+/FcgR) and megakaryocyte/
erythrocyte progenitors (MEP: LK/CD34/FcgR), whereas theCancer Cell 20, 661–number of granulocyte/macrophage progeni-
tors (GMP: LK/CD34+/FcgR+) remained un-
changed and fueled CML development (Fig-
ure 1D; Figure S1B). Finally, the reduction in
lymphoid-lineage cells was correlated with a
8-fold decrease in the number of common
lymphoid progenitors (CLP: Lin/c-Kitlow/
Sca1low/Flk2+/IL7Ra+) (Figure 1D). These BM
changes were also associated with the develop-
ment of an extramedullary hematopoiesis in the
spleen affecting all immature compartments,
except for CLPs (Figures 1C and 1D). Alto-
gether, these results indicate a profound he-
matopoietic remodeling in response to CML
development characterized by the loss of theimmature stem and progenitor compartments in the BM, and
their compensatory increase and redistribution to peripheral
organs.
BCR/ABL Alters the Biology of Several Stem
and Multipotent Progenitor Cells
To assess how BCR/ABL activity affects the biological output of
specific BM populations, we transplanted highly purified stem
and progenitor cells isolated from 5–6-weeks-induced BA mice
into sublethally irradiated congenic recipients (Figure 2A). As ex-
pected, transplantation of BA+ myeloid-committed CMPs and
GMPs (Huntly et al., 2004), but also of lymphoid-committed
CLPs, failed to sustain lasting chimerism in the PB, BM and
spleen and to transplant the disease (Figures 2B and 2C; Fig-
ure S2A). Similarly, transplantation of the two most abundant
populations present in the LSK compartment (i.e., MPPs and
the expanded CD48+ cells) failed to transfer CML, although
transplantation of BA+ MPPs led to a high degree of chimerism
due to a massive production of B cells (Figure S2B). In contrast,673, November 15, 2011 ª2011 Elsevier Inc. 663
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Figure 3. Functional and Molecular Characteriza-
tion of CML Leukemic Stem Cells
(A) Leukemic potential of CML LT-HSCs and ST-HSCs.
Cells were isolated from Cnt and BA mice (CD45.2)
5 weeks after doxycycline withdrawal and transplanted
(500 cells/mouse) into sublethally irradiated recipients
(CD45.1). Transplanted mice were bled at several time
points and analyzed for overall percentage of CD45.2
chimerism (upper graphs) and percent of donor-derived
Mac1+myeloid cells (lower graphs). Results are expressed
as mean ± SEM (n = 2–3; *p % 5 3 102). yIndicates
cohorts found moribund.
(B) Limiting dilution transplantation. Fifty Cnt or BA+
LT-HSCs (CD45.2) were transplanted into sublethally
irradiated recipients (CD45.1) together with 33 105 Sca-1-
depleted BM cells (CD45.1). Graphs show kinetics of
hematopoietic reconstitution in PB and results are ex-
pressed as mean ± SEM (n = 7; **p % 103). yIndicates
cohort found moribund at later time points.
(C) Clonal expansion analyses. The panels show repre-
sentative examples of the percentage of CD45.2 chime-
rism in BMcompartments 160 days after transplantation of
50 BA+ LT-HSCs.
(D) Cell-cycle analyses. LT-HSCs were isolated from Cnt
and BA mice 5 weeks after doxycycline withdrawal. The
left panels show DNA/RNA contents analyzed by 7-AAD
and Pyronin Y staining, and the right panels shows BrdU
incorporation in cells cultured for 1 hr with 60 mM BrdU.
Results are expressed as mean ± SEM (n = 2).
(E and F) Quantitative gene expression analyses. Pools of
100 Cnt and BA+ LT-HSCs were analyzed on a Fluidigm
Dynamic Array IFC for a custommade set of cell cycle and
self-renewal genes, respectively. Results are expressed
as fold change relative to Cnt LT-HSCs (n = 7; **p% 103,
***p% 104, ****p% 105).
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IL-6 in CML Pathogenesistransplantation of either BA+ LT-HSCs or ST-HSCs (4000 cells/
mouse) both induced the development of a robust CML disease,
with the transplanted mice becoming moribund within 1 month
posttransplantation (Figure 2B). Analyses of these mice showed
a clear bias toward myeloid cell production in the BM, spleen,
and PB (Figure 2C; Figures S2A and S2B), together with a severe
reorganization of the stem and progenitor compartments in the
BM (i.e., increased percentage of CD48+ cells and GMPs) (Fig-
ure 2D), infiltration of mature myeloid cells in the liver (Fig-
ure S2C), and development of splenic extramedullary hemato-
poiesis (data not shown). Taken together, these results show
that transplantation of either LT-HSCs or ST-HSCs recapitulates
the core features of the CML disease observed in primary BA
mice, and suggest that two distinct stem cell populations pre-
sent in the LSK compartment may function as LSCs, at least at
high doses of transplanted cells.
Refining the Identity of CML-LSCs
LT- and ST-HSCs are functionally defined by the extent of their
self-renewal capacity (Benveniste et al., 2010). To investigate
how such functional distinctions translated in the context of664 Cancer Cell 20, 661–673, November 15, 2011 ª2011 Elsevier Inc.CML leukemogenesis, we performed trans-
plantation in limiting conditions into sublethally
irradiated recipients (Figure 3A). Although trans-
plantation of either 500 control or BA+ LT-HSCs
or ST-HSCs gave rise to similar levels of PBchimerism, only BA+ LT-HSCs maintained an elevated produc-
tion of myeloid cells that ultimately led to CML development
and death of the recipient mice (93 ± 6 days; n = 3). In contrast,
BA+ ST-HSCs only promoted a transient myeloid hyperplasia
that resulted in the same percentage of circulating myeloid cells
than control ST-HSCs by 50 days posttransplantation. We also
transplanted 50 control or BA+ LT-HSCs into sublethally irradi-
ated recipients to better quantify the number of CML-LSCs pre-
sent in the LT-HSC compartment (Figure 3B). Although we did
not observe significant engraftment from control LT-HSCs under
these highly competitive conditions, six of the seven mice trans-
plantedwith 50BA+ LT-HSCs showed a robust (37.9 ± 4.5%) and
long-lasting (>20 weeks) multilineage PB chimerism. Moreover,
five of the six engrafted mice developed CML and becomemori-
bundwith a latency of 159 ± 24 days, indicating that one out of 40
BA+ LT-HSCs (calculated according to Poisson statistics, data
not shown) is a bona fide CML-LSC. Strikingly, BM analysis of
diseased mice showed that CML-LSCs were able to completely
out-compete the normal hematopoiesis re-emerging from irradi-
ated recipients (Figure 3C). Altogether, these results demon-
strate that CML-LSCs reside exclusively within the LT-HSC
Cancer Cell
IL-6 in CML Pathogenesiscompartment and display a massive competitive advantage at
the clonal level. They also indicate that BA+ ST-HSCs function
as a short-term leukemic progenitor compartment, which
amplifies the myeloid hyperplasia in a manner that might eventu-
ally be fatal upon transplantation of large numbers of cells, but
which cannot per se sustain long-term CML development.
Aberrant Features and Molecular Deregulations
in CML-LSCs
We next investigated how BCR/ABL impacts on the molecular
networks controlling LT-HSC function. We observed a striking
hyperproliferative phenotype in BA+ LT-HSCs (Figure 3D), which
was characterized by a significant loss of quiescence and a
2-fold increase in proliferation rates. We then used a Fluidigm
Dynamic RT-PCR array to perform a detailed quantitative ex-
pression analysis of 96 genes of interest in pools (n = 7) of 100
control and BA+ LT-HSCs (Figure 3F). Consistent with their
increased proliferation, expression of the G2/M cyclins A2
(Ccna2) and B1 (Ccnb1), and their associated cyclin-dependent
kinase 1 (Cdk1), was elevated in BA+ LT-HSCs. We also ob-
served decreased expression of the early G1 cyclin D1 (Ccnd1)
and cyclin-dependent kinase inhibitor p57 (Cdkn1c) in BA+
LT-HSCs, similar to what we have already reported in another
population of LT-HSC-derived LSCs in junB-deficient CML-like
mice (Santaguida et al., 2009). Focusing on self-renewal pro-
grams, we confirmed the previously described downregulation
of Evi1 and Mpl expression in BA+ LT-HSCs (Schemionek
et al., 2010), and found no significant changes in the expression
levels of Bmi1, Pten, Hoxb4, Ikzf1 (Ikaros), and GATA2 (Fig-
ure 3G). Strikingly, we uncovered major alterations in the regula-
tion of the Notch pathway, with significant reduction in the
expression of both Notch1 and its transcriptional target Hes1
in BA+ LT-HSCs. Taken together, these results indicate that
CML-LSCs have a hyperproliferative phenotype that occurs
without loss of self-renewal activity, and leads to clonal domi-
nance. They also suggest that impairment of the Notch signaling
pathway could contribute to the aberrant proliferation and mye-
loid cell production from CML-LSCs as previously reported for
junB-deficient LSCs (Santaguida et al., 2009) and more recently
described in other MPN models (Klinakis et al., 2011).
Transient B Cell Hyperplasia Arising
from Leukemic MPPs
Although both BA+ LT-HSCs and ST-HSCs have an extensive
ability to produce myeloid cells, transplantation of BA+ MPPs
promotes a surprising B cell overproduction (Figures 2B and
2C; Figure S2B). To better understand this phenomenon, we
transplanted control orBA+MPPs (4000 cells/mouse) into suble-
thally irradiated recipients (Figure 4A). Analyses performed at
35 days posttransplantation showed dramatically elevated BM
chimerism in mice transplanted with BA+ MPPs compared to
control MPPs, which consisted mainly of B220+ donor-derived
B cells and reflected a specific increase in CD43+ pro-B cells
with corresponding decreased in CD43 pre-B and IgM+ imma-
ture/mature B cells (Figure 4B). This massive increase in pro-B
cell production from BA+ MPPs was able to completely repress
hematopoietic recovery from sublethally irradiated recipient
mice (Figure S3A). Consistent with this major hematopoietic
disruption, two out of seven transplanted mice were anemicCanandmoribundwhenanalyzed,whereas theothermicedeveloped
extensive splenic extramedullary hematopoiesis and survived
(data not shown). This pro-B cell hyperplasia was specific to
the leukemic MPP compartment, as the output of the down-
stream CLP compartment was not similarly affected by BCR/
ABL activity (Figure 2C and data not shown). In addition, it did
not correspond to the development of B cell acute lymphoblastic
leukemia (B-ALL), as the pro-B cell hyperplasia remained
restricted to the BM (Figures S3B and S3C) and was not
transplantable to secondary recipients (data not shown). Most
notably, this hyperplasia did not persist over time andwas absent
in the surviving mice by 70 days posttransplantation (Figure 4B).
Altogether, these results indicate that BCR/ABL increases and
biases the differentiation potential of MPPs toward the produc-
tion of B cell progenitors at the expense of myeloid cell genera-
tion, but without promoting its oncogenic transformation.
Context-Dependent Behavior of Leukemic MPPs
Although we observed an extensive B-lymphoid potential in
transplanted BA+ MPPs, primary BA mice displayed a reduced
B cell compartment (Figure 1B). To address this paradox, we
cotransplanted 4000 BA+ MPPs together with 4000 BA+ HSCs
(either long-term or short-term) into sublethally irradiated recipi-
ents (Figure 4C). Strikingly, 35 days after cotransplantation, four
out of five recipient mice developed a CML disease (Figure 4C),
which indicated that pathological myeloid expansion driven by
BA+ HSCs was able to repress the B cell expansion promoted
by leukemic MPPs. We then analyzed the biological properties
and molecular regulation of MPPs isolated from primary CML-
developing BA mice. Consistent with their extensive reconstitu-
tion activity upon transplantation, BA+ MPPs exhibit a 2-fold
increase in proliferation rates (Figure 4D). Gene expression anal-
yses of BA+MPPs only revealed marginal changes for genes en-
coding cell cycle regulators (Figure S3D). In contrast we ob-
served a striking increase in the expression levels of myeloid
determinants such as Irf8 or Csf1r (M-CSFR), and a concomitant
decrease in the expression of key lymphoid determinants in-
cluding Notch1, Hes1, Gfi1, Ikzf1 (Ikaros), and Tcf3 (E2A) in
BA+ MPPs (Figure 4E). Taken together, these results indicate
that BA+ MPPs are intrinsically poised toward B lymphoid differ-
entiation but are reprogrammed toward the myeloid fate during
CML development, hence revealing an unexpected context-
dependent behavior for these leukemic MPPs.
CML-Driven IL-6 Production Suppresses Lymphoid
Differentiation from Leukemic MPPs
We reasoned that molecular effectors responsible for the fate
reprogramming of leukemic MPPs could be extracellular sig-
naling molecules detectable in the serum of CML-developing
mice. Analyses performed with an antibody-based protein array
revealed increased levels of a number of cytokines and growth
factors in the serum of primary BAmice (Figure 5A). We focused
on the multifunctional proinflammatory cytokine interleukin-6
(IL-6), which has been previously implicated in both myeloid
expansion and lymphocytopenia (Maeda et al., 2005). Using an
enzyme-linked immunoabsorbent assay (ELISA) on sera and
spleen homogenates, we confirmed increased IL-6 concentra-
tions in all CML-developing mice, either primary BA mice or
BA+ HSCs transplanted mice (Figure 5B). qRT-PCR analysescer Cell 20, 661–673, November 15, 2011 ª2011 Elsevier Inc. 665
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Figure 4. Context-Dependent Behavior of Leuke-
mic MPPs
(A) Reconstitution potential of CML MPPs. Four thousand
Cnt or BA+ MPPs (CD45.2) were transplanted into sub-
lethally irradiated recipient mice (CD45.1). Recipients
(n = 5) were sacrificed and BM reconstitution was analyzed
by flow cytometry 35 days posttransplantation. Repre-
sentative FACS plots showing an example of B cell pro-
genitor reconstitution.
(B) Kinetics of B cell production in recipient BM at 35 (top
panels) and 70 (bottom panels) days posttransplantation.
The left graphs indicate the average percentage of donor-
derived myeloid (Mac1+, black) and lymphoid (B220+/
CD3+, gray) cells. The right graphs show the percentage of
CD43+/IgM pro-B, CD43/IgM pre-B and IgM+ mature
B cells in the donor-derived B220+ cells. Results are
expressed as mean ± SEM (n = 2–5; *p% 53 102, **p%
5 3 103).
(C) In vivo competition between leukemic compartments.
Four thousand BA+ HSCs (either LT-HSCs or ST-HSCs)
together with 4000 BA+ MPPs (both CD45.2) were co-
transplanted into sublethally irradiated recipient mice
(CD45.1). The right graph shows the percentage of donor-
derived myeloid and lymphoid cells in the BM of recipient
mice 35 days posttransplantation. Of note, four of five
mice developed a myeloid disease (CML) and one mouse
a lymphoid hyperplasia (LH).
(D) Cell-cycle distribution. BrdU incorporation in MPPs
isolated from Cnt and BA mice 5 weeks after doxycycline
withdrawal and cultured for 1 hr with 60 mM BrdU. Results
are expressed as mean ± SEM (n = 2).
(E) Quantitative gene expression analyses. Pools of 100
Cnt and BA+ MPPs were analyzed on a Fluidigm Dynamic
Array IFC for a custom made set of genes regulating
myeloid versus lymphoid lineage specification. Results are
expressed as fold change relative to Cnt MPPs (n = 7; *p%
102, **p% 103, ****p% 105). See also Figure S3.
Cancer Cell
IL-6 in CML Pathogenesisdemonstrated that the expanded myeloid CML cells were the
major source of IL-6 production during disease development
(Figure 5C), whereas flow cytometry studies indicated that the
receptor for IL-6 (IL-6Ra) was detectable on both control and
BA+ MPPs and downstream myeloid progenitors, but not on
the most immature LT-HSCs or ST-HSCs (Figure 5D). Strikingly,
addition of murine recombinant IL-6 completely blocked the
ability ofBA+MPPs to generate CD19+ B cells in vitro (Figure 5E).
In addition, IL-6 dramatically increased the numbers and size
of myeloid colonies generated from BA+ MPPs in methylcellu-
lose clonogenic assays, whereas no significant effects were
observed from BA+ GMP in the same conditions (Figure 5F).
Taken together, these results indicate that the IL-6 secreted by
the expanded myeloid CML cells directly acts on leukemic
MPPs and redirects their aberrant BCR/ABL-driven intrinsic B
cell potential toward the myeloid lineage (Figure 5G).
In Vivo Cross-Talk between Leukemic and Nonleukemic
Hematopoietic Compartments
In CML patients, the leukemic cells coexist and compete with
normal hematopoiesis. To model such interactions and validate666 Cancer Cell 20, 661–673, November 15, 2011 ª2011 Elsevier Inc.the function of IL-6 in these relevant condi-
tions, we cotransplanted 2 3 106 wild-type
(WT: CD45.2 GFP+) along with 2 3 106 nonin-duced BA (CD45.2 GFP) unfractionated BM cells into lethally
irradiated recipients (CD45.1 GFP) maintained under doxycy-
cline (Figure 6A). As expected, WT and noninduced BA cells
showed a similar 50:50 chimerism at 2 months posttransplan-
tation (Figure 6B). Upon doxycycline withdrawal, four of five
transplanted mice developed CML with disease onset ranging
from 40 to 154 days (median 99 days; n = 4). Strikingly, the
50:50 chimerism was preserved in CML-developing mice, with
both WT and BA+ cells contributing to the expanded mature
myeloid cells (Figure 6B). We also confirmed increased con-
centrations of IL-6 in the serum of CML-developing mice (Fig-
ure 6C). Interestingly although BA+ cells were overrepresented
within the LT-HSC and ST-HSC compartments (85.8% ± 5.1
and 82.4% ± 6.1 respectively; mean ± SEM; n = 2), the MPP
compartment displayed an equal contribution of BA+- and
WT-derived cells (50.9% ± 1.3 BA+ cells, mean ± SEM,
n = 2) similar to the 50:50 chimerism found in the expanded
myeloid lineage. Taken together, these results confirm in vivo
that lineage determination can be controlled by systemic
factors downstream of CML-LSCs, and correlate the increase
in IL-6 production driven by myeloid CML cells with the
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Figure 5. IL-6 Paracrine Loop
(A) Protumorigenic inflammatory environment during CML
development. Changes in the indicated growth factor and
interleukin levels were determined using an antibody-
based protein array on pools of sera from 16 Cnt and 7 BA
mice 6 weeks after doxycycline withdrawal. Results are
expressed as fold change relative to levels measured in
Cnt mice (set to 1).
(B) Modulation of serum IL-6 levels. ELISA measurement
of IL-6 concentration in serum of individual Cnt and BA
primary mice (left graphs), and mice transplanted with
the indicated populations (right graphs). Results are ex-
pressed as mean ± SEM (n = 2–6). ND, not detectable.
(C) qRT-PCR analysis of nonhematopoietic BM cells
(stroma), CD48+, MPP, CMP, GMP,maturemyeloid, and B
cells for Il-6 mRNA levels. Results are expressed as
mean ± SEM (n = 3).
(D) Representative FACS histograms showing expression
of the a chain of IL-6 receptor on the indicated Cnt (black)
and BA+ (red) populations. Dashed lines show isotype
control negative boundaries. Data are representative of
two independent experiments.
(E) Effect of IL-6 on lymphoid differentiation from BA+
MPPs. The FACS plots show a representative phenotypic
analysis of CD19 (lymphoid) and Mac-1 (myeloid) markers
after 8 days of in vitro culture (n = 2).
(F) Differential effect of IL-6 on myeloid differentiation from
BA+ MPPs and GMPs. The graph on the left show the fold
changes in colony numbers when comparing conditions
with or without IL-6 (set to 1). Results are expressed as
mean ± SEM (n = 2–3; **p% 5 3 104). The photographs
on the right show representative myeloid colonies gener-
ated in both conditions from BA+ MPPs after 10 days of
in vitro culture.
(G) Model describing the IL-6 paracrine loop in CML
development identified in this study.
Cancer Cell
IL-6 in CML Pathogenesisre-routing of both leukemic and normal MPPs toward the mye-
loid lineage.
IL-6 Contributes to CML Development
To confirm the function of IL-6 in CML pathogenesis, we evalu-
ated disease progression in the absence of IL-6 signaling by
crossing BA mice with Il-6/ mice (Kopf et al., 1994). Upon
doxycycline withdrawal, both BA Il-6/ and BA Il-6+/ mice
displayed significantly increased overall survival compared to
BA Il-6+/+ mice (Figure 7A). Consistent with IL-6 serum con-
centrations (Figure 7B), we observed a stepwise decreased in
myeloid cell production together with a stepwise recovery of B
cell generation in the BM of BA Il-6+/ and Il-6/ mice (Fig-
ure 7C). These effects were specific to Il-6 inactivation because
disruption of other cytokine signaling pathways, such as GM-
CSF signaling, in BA mice did not affect CML development
(data not shown). Interestingly, the lymphoid restoration
observed in BA Il-6/ mice also displayed aberrant pro-B cell
features (Figure 7C) similar to the pro-B cell expansion observed
upon transplantation of purified BA+ MPPs (Figure 3B). In addi-
tion, BA Il-6/ mice maintained a high level of myeloid cellsCancer Cell 20, 661–circulating in the PB due to their extensive extra-
medullary hematopoiesis (data not shown), and
eventually succumb to late onset CML diseases
without developing overt lymphoid malignan-cies. Altogether, these results demonstrated that IL-6 signaling
normally blocks the aberrant BCR/ABL-driven pro-B cell poten-
tial of leukemic MPPs and enhances myeloid differentiation,
hence leading to a positive feedback loop promoting CML devel-
opment. They also indicate that IL-6 blocking strategy can signif-
icantly delay CML onset in situations where BCR/ABL remains
active.
BCR/ABL Controls Il-6 Expression in Myeloid CML Cells
Finally, we investigated themechanisms controlling IL-6 produc-
tion using human leukemic cell lines and samples from CML
patients. BCR/ABL-expressing K562 erythro-leukemic cells
and HL60 promyelocytic leukemia cells engineered to stably
express BCR/ABL (Porosnicu et al., 2001) displayed high levels
of IL-6 mRNA, which could be rapidly downregulated by inhibi-
tion of BCR/ABL activity with TKIs (Imatinib or Dasatinib) (Fig-
ure 8A). This effect was specific to IL-6 because the expression
of BCR/ABL and other components of the IL-6 signaling path-
way, including IL-6Ra, were not similarly affected by TKI treat-
ment. For both cell lines, ELISA analyses confirmed that changes
in IL-6 gene expression correlated with changes in the levels of673, November 15, 2011 ª2011 Elsevier Inc. 667
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Figure 6. Contribution of IL-6 to Lineage Determi-
nation In Vivo
(A) Experimental scheme where 5 3 106 wild-type (tWT:
CD45.2 GFP+) and 5 3 106 noninduced BA+ (tBA: CD45.2
GFP) BM cells were cotransplanted into lethally irradiated
recipients (CD45.1). Transplanted mice were maintained
on doxycycline for 2 months to achieve stable reconsti-
tution before inducing BA expression by doxycycline
withdrawal. Mice were analyzed either pre- or post-BA-
induction, when mice displayed signs of CML disease.
(B) Representative FACS plots showing contribution of
tWT and tBA cells to the myeloid (Mac1+/Gr1+) BM output
pre (top) and post (bottom) induction (nR 2).
(C) Concentration of IL-6 in the serum of transplantedmice
pre- and postinduction. Results are expressed as mean ±
SEM (n = 2–4).
(D) Representative FACS plots showing contribution of
tWT and tBA cells to the indicated BM compartments
postinduction (n = 2).
Cancer Cell
IL-6 in CML PathogenesisIL-6 protein secreted in the culture supernatant (Figure 8B). We
then investigated TKI-treatedK562 cells for expression of a panel
of effectors genes known to regulate IL-6 expression (Figure 8C).
We found a significant downregulation of both LIN28 and LIN28b
expression and a considerable increase in BCL6 expression.
BCL6 is a direct transcriptional repressor of the IL-6 gene (Yu
et al., 2005), and recent work has shown that BCR/ABL-driven
STAT5 activation inhibits BCL6 expression (Duy et al., 2011).
Although the regulation of LIN28/28b by BCR/ABL is still largely
unknown, they have been shown to inhibit the maturation of the
Let-7 microRNA, which is itself a negative regulator of IL-6 ex-
pression (Iliopoulos et al., 2009). Therefore, we propose that
pharmacological inhibition of BCR/ABL activity increased BCL6
levels and, as shown here, decreased LIN28/28b levels (Fig-
ure 8C), which could both contribute to the downregulation of
IL-6 expression observed in TKI-treated K562 cells (Figure 8D).
BCR/ABL levels have also been shown to increase with disease
progression (Savona and Talpaz, 2008) and elevated levels of
IL-6 protein have been observed in the serum of accelerated
and myeloid blasts crisis patients (Anand et al., 1998). Consis-
tently, we observed a striking upregulation of IL-6 expression
during CML development in a large cohort of chronic, acceler-
ated and blast crisis phaseCML samples analyzed bymicroarray
(Figure 8E). Furthermore, we noticed an accompanying decrease668 Cancer Cell 20, 661–673, November 15, 2011 ª2011 Elsevier Inc.in BCL6 expression, particularly in blast crisis
samples (Figure 8E), whereas upregulation of
LIN28 during CML progression has been previ-
ously reported (Viswanathan et al., 2009). Taken
together, these results demonstrate that BCR/
ABL activity controls IL-6 expression in myeloid
CML cells, and suggest that both BCL6 and
LIN28/28b are involved in the complex molec-
ular network mediating this effect.
DISCUSSION
In this study, we use an inducible BCR/ABL
transgenic mouse model that recapitulates the
main features of human chronic phase CML.This allows us to considerably improve on the phenotypic and
functional characterization of CML-LSCs, and to segregate
them from two newly identified nonself-renewing leukemic multi-
potent progenitor populations that are present in the LSK frac-
tion of the BM. These results unambiguously prove the long-
standing concept that CML arise from transformed HSCs, and
demonstrate that the clinically relevant CML-LSCs are solely
contained in the rare LT-HSC compartment. This finding is
essential to identify therapeutic targets that are specific to
CML-LSCs and not to the most abundant leukemic multipotent
progenitors, as currently done with the loose LSK definition of
CML-LSCs. Moreover, we describe how leukemic multipotent
progenitors contribute to CML development, and the essential
function played by the protumorigenic inflammatory environ-
ment in controlling disease pathogenesis.
CML-LSCs
Here, we demonstrate that CML-LSCs are exclusively contained
in the rare LT-HSC compartment, which represent <10% of the
LSK BM fraction (Warr et al., 2011). This level of resolution allows
us to investigate the aberrant features that are specific to CML-
LSCs, and to identify key deregulated mechanisms that could be
amenable to targeted therapy. Based on phenotypic analysis
and serial transplantation of BCR/ABL-expressing LSK cells, it
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Figure 7. Role of IL-6 in CML Development
(A) Survival curve of Cnt (n = 11) and Il-6+/+ (n = 11), Il-6+/
(n = 12), and Il-6/ (n = 17) BA mice after doxycycline
withdrawal (*p% 5 3 102).
(B) ELISA measurement of serum IL-6 levels in Cnt and
Il-6+/+, Il-6+/, and Il-6/ BA mice. Results are expressed
as mean ± SEM (n = 7). ND, not detectable.
(C) Percentage of Mac1+ myeloid (left) and B220+
B-lymphoid (right) cells in BM of individual control and
Il-6+/+, Il-6+/, and Il-6/ BA mice (n = 5–10; *p % 5 3
102, ***p% 5 3 104).
(D) Representative FACS plots showing the phenotype of
B cell progenitors generated in Cnt and Il-6+/+, Il-6+/, and
Il-6/ BA mice. zIndicates that FACS plots is represen-
tative of three out of five analyzed mice with this genotype.
Cancer Cell
IL-6 in CML Pathogenesishas been recently suggested that BCR/ABL activity induces loss
of HSC self-renewal capacity and promotes differentiation
(Schemionek et al., 2010). Indeed, we observe a profound re-
organization of the LSK BM compartment following CML devel-
opment, with a severe reduction in the numbers LT-HSCs, ST-
HSCs, and expansion of nonself-renewing LSK/Flk2/CD48+
cells and Flk2+ MPPs. However, we find that such changes in
the BM are associated with the development of a massive
myelofibrosis, and are fully compensated for by the emergence
of extramedullary hematopoiesis with increased numbers of
LT-HSCs in the spleen. Most importantly, we observe that
BCR/ABL-expressing LT-HSCs are able to self-renew exten-
sively and to out-compete normal LT-HSCs, both in stress
conditions upon transplantation in sublethally irradiated recipi-
ents, and in steady-state conditions when BCR/ABL expression
is induced in transplanted mice harboring chimeric hematopoi-
esis. This property is consistent with the clonal dominance
observed in human CML patients, where the majority of CD34+
stem and progenitor cells carry the BCR/ABL translocation
(Holyoake et al., 1999). These findings are also in line with ourCancer Cell 20, 661–recent findings in the junB-deficient CML-like
model, where increase proliferation in trans-
formed LT-HSCs is also not associated with a
loss of self-renewal capacity (Santaguida et al.,
2009). Consistent with this idea, BCR/ABL
activity does not dramatically disrupt the tran-
scriptional networks regulating LT-HSC self-
renewal. More strikingly, we observe significant
changes in cell cycle machinery and decrease
expression of Notch signaling components in
BCR/ABL-expressing LT-HSCs that are similar
to the deregulations we previously described
in junB-deficient LT-HSCs (Santaguida et al.,
2009). These findings reinforce the idea that
deregulation of the Notch pathway is a key con-
tributor to aberrant myelopoiesis (Klinakis et al.,
2011), and that loss of quiescence and resulting
hyperproliferation in transformed LT-HSCs may
occur through a dampening of the cyclin D1/
Cdkn1c (p57) regulatory axis (Pietras et al.,
2011). They also suggest that LT-HSC transfor-
mation may, in fact, result from the perturbation
of a few common regulatory pathways regard-less of the initiating oncogenic event and that strategy aimed
at restoring Notch activity in transformed LT-HSCs may repre-
sent a valid therapeutic approach to targeted LSC aberrant
activity in CML and other type of MPNs.
CML Multipotent Progenitors
Here, we also demonstrate that BCR/ABL expression affects the
activity of ST-HSCs and MPPs, but not of any other tested
lineage-committed progenitors. BCR/ABL activity increases
cell cycling and considerably expands the output of both ST-
HSCs and MPPs, thereby providing these leukemic progenitors
with extensive, although transient, in vivo reconstitution ability
upon transplantation. Strikingly, opposite lineage outputs were
generated from these transplanted cells, with leukemic ST-
HSCs, like CML-LSCs, giving rise to a generalized myeloid
hyperplasia, and leukemic MPPs producing a massive accumu-
lation of pro-B cells in the BM. These results indicate that BCR/
ABL exerts cell-type specific effects and biases the lineage
potential of specific multipotent progenitor cells based on their
stage of maturation and, likely, the permissiveness of their673, November 15, 2011 ª2011 Elsevier Inc. 669
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Figure 8. BCR/ABL Controls Il-6 Expression
(A) BCR/ABL-dependent IL-6 expression in human
cell lines. qRT-PCR analysis of IL-6 pathway com-
ponents in K562 (left) and BCR/ABL-expressing
HL60 (right) cells with or without TKI treatment.
Results (mean; n = 2–4) are expressed as fold
change relative to untreated K562 (left) or Mock-
transfected HL60 (right) cells (mean; n = 2–4;
*p < 0.05).
(B) ELISA measurement of IL-6 concentration in
the supernatant of the cell lines used in (A). Results
are expressed as mean ± SEM (n = 2).
(C) qRT-PCR analysis of BCR/ABL signaling
pathway components in K562 cells with or without
TKI treatment. Results (mean; n = 4) are expressed
as fold change relative to untreated K562 cells.
(D) Proposed model for BCR/ABL regulation of
IL-6 expression. In CML cells, BCR/ABL stimu-
lates LIN28 production, which in turn blocks Let-7
microRNA maturation (Iliopoulos et al., 2009)
and/or blocks BCL6 expression (Duy et al., 2011)
hence allowing transcription of the IL-6 gene.
Inhibition of BCR/ABL activity by TKI treatment
reduces LIN28 expression and/or releases BCL6
expression hence allowing them to block IL-6
expression (Yu et al., 2005).
(E) Expression of IL-6 (p < 0.05) and BCL6 (p <
0.0001) in BM or PB from chronic (gray), acceler-
ated (blue), and blast crisis (red) phase CML
patients relative to the expression in a pool of 200
chronic phase patients. Expression is in loga-
rithmic scale. Data was analyzed using Qlucore
Omics Explorer (Qlucore, AB, Lund, Sweden). The
software performs a multigroup comparison using
the ANOVA F-test.
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CML develops from transformed LT-HSCs through a continuum
of leukemic progenitor cells that are devoid of self-renewal
activity but have defined aberrant properties. As we observe
here, such nonself-renewing leukemic progenitors can easily
kill a mouse when transplanted at high doses and generate a
disease, which despite being not transplantable, closely mimics
CML both in kinetic and phenotype. This can have a confusing
effect especially when transplanting high numbers of transduce
mix populations such as 5-FU treated BM or LSK cells. Caution
should therefore be taken in interpreting the results of retroviral
transduction/transplantation experiments, particularly when as-
sessing the effect on CML-LSC numbers through serial trans-
plantations, and on themyeloid/lymphoid nature of the emerging
disease.
Protumorigenic Inflammatory Environment in CML
Pathogenesis
Our results unveil an essential paracrine mechanism involving
the proinflammatory cytokine IL-6, which serves as a positive
feedback loop to sustain CML development and acts at the level670 Cancer Cell 20, 661–673, November 15, 2011 ª2011 Elsevier Inc.of leukemic MPPs by reprogramming
them toward myeloid development at
the expense of their intrinsic BCR/ABL-
driven lymphoid-bias potential. CML de-velopment is accompanied by considerable changes in the
proinflammatory tumor environment. Autocrine or paracrine
mechanisms involving IL-3, G-CSF or GM-CSF have been re-
ported to enhance the proliferation and viability of primitive
CML cells both in mouse models and human samples (Jiang
et al., 1999; Zhang and Ren, 1998). However, the real contribu-
tion of these pathways to CML development remains unclear
as their inactivation in the mouse does not significantly affect
disease outcome (Li et al., 2001). Here, we identify IL-6 as a
key cytokine whose expression and secretion by myeloid cells
is most affected by CML development, which confirms earlier
findings in serum of CML patients (Anand et al., 1998) and very
recent observations using the retroviral transduction/transplan-
tation model of CML (Schmidt et al., 2011). IL-6 exerts multiple,
and some time divergent, functions on hematopoietic cells,
including the provision of instructive cues for myeloid differenti-
ation in normal contexts and in mouse models of inflammation or
autoimmune diseases (Maeda et al., 2005, 2009). Here, we show
that the IL-6 receptor expression starts at the MPP stage of
hematopoietic differentiation and is not affected by BCR/ABL
activity. We demonstrate that IL-6 acts on both normal and
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IL-6 in CML Pathogenesisleukemic MPPs to redirect their differentiation potential toward
the myeloid lineage at the expense of lymphoid differentiation.
Furthermore, we show unambiguously by a genetic approach
in themouse that impairment of IL-6 signaling delays CML devel-
opment, hence confirming the essential contribution of this
pathway as a feedback loop supporting chronic phase CML.
This paracrine mechanism appears exacerbated in CMLmyeloid
blast crisis, most likely due to increased IL-6 production by blast
cells as shown here by genome-wide genes expression analyses
of CML patient samples. Disruption of the IL-6 paracrine loop,
either through mutations in the IL-6 signaling pathway or loss
of IL-6 production, and subsequent release of CML-MPP in-
trinsic B-lymphoid potential may also constitute the first step in
the otherwise apparently random myeloid/lymphoid conversion
observed during CML progression to lymphoid blast crisis. In-
structive signals controlling the myeloid/lymphoid balance in
CML is reminiscent to what has been described in MLL-rear-
ranged AML, where growth factors and cytokines can instruct
the lineage fate of multipotent LSCs (Barabe´ et al., 2007). Taken
together, these findings demonstrate that blood cancers, like
solid cancers, are profoundly affected by the protumorigenic
inflammatory environment in which leukemic stem and progen-
itor cells reside and function.
IL-6 Signaling As a Target for CML Therapy
IL-6 has been previously implicated in the pathogenesis of
hematological malignancies (i.e., multiple myeloma, Hodgkin’s
lymphoma) and solid cancers (i.e., breast, prostate, and recently,
pancreatic cancers) (Hong et al., 2007). Here, we identify IL-6 as
a major player in CML pathogenesis. We demonstrate that BCR/
ABL activity dictates the level of IL-6 produced by both mouse
and human myeloid CML cells. We show that BCR/ABL regu-
lates IL-6 mRNA levels through a complex and indirect mecha-
nism involving, at least, BCL6 and the LIN28/28b-Let-7 pathway,
which are two known transcriptional regulators of the IL-6 gene
(Iliopoulos et al., 2009; Yu et al., 2005). We find that pharmaco-
logical inhibition of BCR/ABL activity with TKIs restore IL-6
expression and production to its normally low levels. We also
show that disruption of the IL-6 paracrine loop through genetic
ablation of the Il-6 gene in mice significantly delays CML onset
despite persistent BCR/ABL activity. These results suggest
that therapies aimed at blocking IL-6 or targeting the IL-6 signal
transduction pathway, although noncurative, could provided
clinical benefits for CML patients that develop resistance to
TKI treatment or undergo myeloid blast crisis progression. One
important concern is that the aberrant B cell expansion driven
by CML-MPPs and observed upon IL-6 inactivation may repre-
sent a preleukemic stage, which could evolve into an aggressive
B-ALL upon acquisition of additional mutations (Mullighan et al.,
2008). However, no lymphoid malignancies have spontaneously
developed over time in aged BA Il-6/ mice (n = 17; data not
shown), and we are currently performing additional genetic
experiments in BA Il-6/ mice to directly test this hypothesis
and address the safety of IL-6 blocking therapies. Finally, it is
tempting to speculate that such self-reinforcing paracrine loop
involving IL-6, or other secreted proinflammatory factors, might
be relevant in a broad spectrum of myeloid disorders. It opens
the possibility of combinatorial strategies targeting not only the
bulk tumor cells and the LSC compartment but also the protu-Canmorigenic inflammatory environment, which controls the func-
tion of the leukemic hierarchy. Such a three-pronged approach
might, in fact, be needed to develop curative treatment for
CML and other types of blood malignancies.
EXPERIMENTAL PROCEDURES
Mice
Scl/Tal-1-tTA and TRE-BCR/ABL mice were backcrossed for at least nine
generations in the C57Bl/6 background and were interbred in presence of
20 mg/l doxycycline (Sigma-Aldrich) in their drinking water. Il-6/ mice
were purchased from the Jackson laboratory. Transplantations were per-
formed as previously described (Santaguida et al., 2009). All animal experi-
ments were performed in accordance with UCSF IACUC approved protocols.
Flow Cytometry
Staining and enrichment procedures for stem and progenitor population sort-
ing and analysis were performed as previously described (Santaguida et al.,
2009). Cells were sorted or analyzed on a FACS ARIAII or LSRII (Becton Dick-
inson), respectively.
Cell Culture
For myeloid differentiation assays, 500 MPPs or GMPs were plated in 10 mm
dishes in methylcellulose (StemCell Technology, M3231) supplemented with
SCF (25 ng/ml) and Flt3L (25 ng/ml) in the presence or absence of IL-6
(20 ng/ml) (Peprotech) and grown for 2 weeks. For B cell differentiation assays,
cells were plated on OP9 stromal cells in OptiMEM medium (Invitrogen) sup-
plemented with 5% FBS (StemCell Technology), SCF (10 ng/ml), Flt3L
(10 ng/ml), and IL-7 (5 ng/ml). Following sequential withdrawal of Flt3L and
SCF upon 2-day intervals, cultures were maintained in IL-7 and analyzed at
day 8 by flow cytometry. K562 and HL60 human cell lines were cultured for
15–20 hr in RPMI medium supplemented with 10% FBS in presence or
absence of TKI (5 mM Imatinib or 100 nM Dasatinib).
Protein Array and ELISA
Antibody-based protein array (Proteome Profiler, R&D Systems) and IL-6
ELISA assays (eBioscience) were performed on sera according to the manu-
facturer’s instructions. The assay detection range was 5–1000 pg/ml.
Proliferation Assays
Intracellular BrdU staining and 7AAD/Pyronin Y staining were performed as
previously described (Santaguida et al., 2009).
Quantitative RT-PCR Array
Quantitative RT-PCR arrays were performed on the Fluidigm 96.96 Dynamic
Array IFC platform. Intron-spanning sets of primers for preamplification and
quantitative PCR were validated on serial dilution of total mouse cDNA to
ensure linear amplification, PCR specificity, and performance. One hundred
cells were directly sorted in 5 ml of resuspension buffer from Cellsdirect One-
Step qRT-PCR kits (Invitrogen). Samples were used for random hexamer-
based reverse-transcription (SuperScript III kit, Invitrogen) and preamplified
for 18 cycles with Platinium Taq DNA polymerase (Invitrogen) and primer
mix (50 nM). Resulting cDNA products were analyzed on Fluidigm BioMark
System using EvaGreen dye (Biotium). Each measurement was performed in
triplicate and expression levels ofGusb,Gapdh, Pgk1, and Cltc housekeeping
genes were used for normalization.
Microarray Gene Expression Studies
Gene expression profiles of CML patient samples have been described previ-
ously (Radich et al., 2006; GEO accession number 4170). This published data
set was analyzed for the expression of IL-6 and BCL6 in BM and PB samples
from 42 chronic, 17 accelerated, and 32 blast crisis phase CML patients.
Statistics
All the data are expressed as mean ± standard error of the mean (error bar)
except when indicated. The p values were generated using unpaired Student’s
t test and considered significant when%0.05. For survival curve, p valueswerecer Cell 20, 661–673, November 15, 2011 ª2011 Elsevier Inc. 671
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experiments performed.
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